导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.28% | 3156/4773 |
| 近一周 | 0.04% | 1184/5467 |
| 近一月 | -7.46% | 3478/5421 |
| 近一季 | 11.55% | 179/5238 |
| 近半年 | -2.82% | 2481/4931 |
| 近一年 | -16.07% | 3757/4400 |
| 近两年 | 18.33% | 2679/2954 |
| 近三年 | -11.37% | 2050/2253 |
| 成立以来 | 31.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.66% 2419/4961 |
-6.49% 3705/5312 |
- - |
- - |
| 2025 | 5.34% 3006/4813 |
0.82% 1762/3635 |
2.14% 1825/4076 |
17.11% 2556/4524 |
-12.65% 4266/4813 |
| 2024 | -12.64% 2384/3463 |
-11.21% 2418/2808 |
-9.23% 2337/3014 |
19.86% 797/3129 |
-9.57% 2935/3463 |
| 2023 | -11.77% 1424/2656 |
0.16% 1755/2280 |
-7.98% 1942/2385 |
-1.72% 569/2515 |
-2.59% 496/2655 |
| 2022 | -21.84% 1053/2207 |
-13.10% 698/1919 |
-0.13% 1598/2016 |
-17.78% 1645/2113 |
9.53% 210/2208 |
| 2021 | -11.40% 1109/1822 |
-3.32% 799/1255 |
14.81% 244/1330 |
-15.62% 1388/1466 |
-5.40% 1509/1822 |
| 2020 | 52.00% 155/1250 |
6.31% 44/1028 |
30.14% 63/1067 |
3.84% 967/1164 |
5.80% 774/1184 |
| 2019 | 31.57% 463/1092 |
28.09% 325/754 |
-7.03% 538/804 |
5.63% 140/850 |
4.60% 795/918 |
| 2018 | -25.13% 340/834 |
- - |
- - |
- - |
-20.63% 668/691 |
| 2017 | 13.42% 264/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.91% 311/605 |
- - |
- - |
- - |
- - |
| 2015 | 41.25% 41/575 |
- - |
- - |
- - |
- - |
| 2014 | 10.30% 207/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 汇添富中证医药卫生ETF VS. 长安沪深300非周期A(740101) |